Logo
x

Search

Subscribe Now

Lupin

Lupin Reports the P-III Study Completion of LUBT010 (Biosimilar, Lucentis) for Neovascular Age-related Macular Degeneration

Lupin Reports the P-III Study Completion of LUBT010 (Biosimilar, Lucentis) for Neovascular Age-related Macular Degeneration

  • August 5, 2024
Lupin and Sandoz Launch Rymti (Biosimilar, Enbrel) in Canada to Treat Plaque Psoriasis

Lupin and Sandoz Launch Rymti (Biosimilar, Enbrel) in Canada to Treat Plaque Psoriasis

  • May 3, 2024
Lupin Obtains the US FDA Approval for Loteprednol Etabonate Ophthalmic Suspension

Lupin Obtains the US FDA Approval for Loteprednol Etabonate Ophthalmic Suspension

  • January 2, 2024
Lupin and Amman Pharma Signs an Exclusive Agreement for Licensing and Supply of Ranibizumab (Biosimilar, Lucentis)

Lupin and Amman Pharma Signs an Exclusive Agreement for Licensing and Supply of Ranibizumab (Biosimilar, Lucentis)

  • November 10, 2023
Lupin Collaborated with Enzene Biosciences to Launch Cetuximab in India

Lupin Collaborated with Enzene Biosciences to Launch Cetuximab in India

  • May 30, 2023
Lupin Entered into an Exclusive License and Supply Agreement with DKSH to Commercialize Five Biosimilar Candidates in the Philippines

Lupin Entered into an Exclusive License and Supply Agreement with DKSH to Commercialize Five Biosimilar Candidates in the Philippi...

  • September 7, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.